Easy to use kits measuring real-time energy flux, substrate utilization and mitochondrial function in living cells, without the need for expensive analysers.
Advanced high throughput disease models and assays for early prediction of drug toxicity, mitochondrial liability and mechanistic characterization.
Measure and monitor oxygen throughout the cell culture workflow. Multiplex assays for intracellular / extracellular oxygen concentration and ROS.
Get in Touch
To Register Interest or Order ProductsMake Enquiry
Webinar REGISTER NOW- “Defining Physiological Normoxia in Cultured Cells for Translation to Animal Models and Man”
On October 25th at 7am PDT/ 3pm BST, Professor Giovanni Mann from Kings College London will lead a webinar in conjunction with Nature Publishing describing exciting new work conducted in collaboration with Luxcel Biosciences and, webinar sponsor, BMG LABTECH. Highlighting the importance of conducting in vitro research under oxygen conditions encountered in vivo, speakers will describe the tools necessary to recapitulate such conditions on the bench and will share new data describing the significant impact this has on key experimental outcomes.
Glycolysis a Central Player in Disease Progression
Recent research across a diversity of fields is fuelling a renewed interest in glycolytic flux measurements, as glycolysis is highlighted again and again as a central player in disease progression and related metabolic adaptation. This is particularly true in areas such as Cancer, Hypoxia, Diabetes, Stem Cell biology and Immunometabolism. Glycolytic activity can be conveniently assessed by measuring lactate-derived acidification and, using the pH-Xtra™ Glycolysis Assay, this is now possible on conventional fluorescence plate readers. Combined with NEW pH-Xtra™ Stress Test, researchers now have the tools to conveniently and comprehensively characterise both basal glycolysis and glycolytic capacity, while avoiding the need for expensive dedicated instrumentation and complicated corrections for CO2 derived acidification.
Luxcel Biosciences Ltd Announce Further EU H2020 Success with €1.5million Award and Rapid Expansion Plans
Luxcel Biosciences Ltd is delighted to announce a further European H2020 funding award, supporting the €1.5million MetaTox-HS product development, under the highly prestigious SME Instrument (SMEInst-02-2016-2017). Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for in vitro scientific tests and models of disease that better replicate drug effect in the patient (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.
MetaCell, Cell Metabolism Made Easy
Led by Luxcel Biosciences, the consortium of Axiogenesis AG, BMG LABTECH GmbH and Luxcel supported by leading academic institutes Oxford University UK and Imperial College London are actively demonstrating a Gold Standard platform, comprising cell assays, disease models and services, together with high performance metabolism tests designed for use on laboratory standard instrumentation – the multi-mode microtiter plate reader.
This project funded by the EU H2020 Fast Track to Innovation initiative is called, MetaCell-TM, metabolism analysis made easy for Cell Translational Medicine.